"Hyperkalemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)
| Descriptor ID |
D006947
|
| MeSH Number(s) |
C18.452.950.396
|
| Concept/Terms |
Hyperkalemia- Hyperkalemia
- Hyperkalemias
- Hyperpotassemia
- Hyperpotassemias
|
Below are MeSH descriptors whose meaning is more general than "Hyperkalemia".
Below are MeSH descriptors whose meaning is more specific than "Hyperkalemia".
This graph shows the total number of publications written about "Hyperkalemia" by people in this website by year, and whether "Hyperkalemia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hyperkalemia" by people in Profiles.
-
Stickle DF, Koob KR, McCudden CR. Characterizing ability of serum potassium (K) and the serum K reference interval to flag hypokalemia or hyperkalemia as observed in plasma: A simulation study. Clin Biochem. 2023 Aug; 118:110606.
-
Drumheller BC, Tuffy E, Gibney F, Stallard S, Siewers C, Korvek S. Severe bradycardia from severe hyperkalemia: Patient characteristics, outcomes and factors associated with hemodynamic support. Am J Emerg Med. 2022 05; 55:117-125.
-
Qin L, Zhang N, Ishigami J, Miller ER, Pfister M, Moran AE, Cox E. Dyskalemia risk associated with fixed-dose anti-hypertensive medication combinations. J Hum Hypertens. 2022 11; 36(11):989-995.
-
Turban S, Juraschek SP, Miller ER, Anderson CAM, White K, Charleston J, Appel LJ. Randomized Trial on the Effects of Dietary Potassium on Blood Pressure and Serum Potassium Levels in Adults with Chronic Kidney Disease. Nutrients. 2021 Jul 31; 13(8).
-
Ackerman BH, Patton ML, Guilday RE, Haith LR, Stair-Buchmann M, Reigart CL. Trimethoprim-induced hyperkalemia in burn patients treated with intravenous or oral trimethoprim sulfamethoxazole for methicillin-resistant Staphylococcus aureus and other infections: nature or nurture? J Burn Care Res. 2013 Jan-Feb; 34(1):127-32.
-
Leming MK, Breyer MJ. Renal failure in a patient with postpolio syndrome and a normal creatinine level. Am J Emerg Med. 2012 Jan; 30(1):247.e1-3.
-
Rodriguez MA, Helms E, Shubert J, Pavri BB. Pacemaker malfunction induced by a pharmaco-metabolic "perfect storm": a brief report. J Clin Pharmacol. 2011 Jan; 51(1):107-9.
-
Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bola?os-Meade J, Greer JM, Carraway HE, Gore SD, Jones RJ, Levis MJ, McDevitt MA, Doyle LA, Wright JJ. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res. 2010 Jul; 34(7):877-82.
-
Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail. 2008 Feb; 10(2):157-63.
-
Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol. 2007 Nov 13; 50(20):1959-66.